Merck KGaA’s Oschmann Sees U.S. as New Emerging Market
This article is for subscribers only.
Merck KGaA, the German drugmaker whose U.S. unit was expropriated almost a century ago, is turning back to that market as competitors focus on emerging economies in Asia and South America.
“For us, the U.S. is an emerging market,” Stefan Oschmann, head of pharmaceuticals, said in an interview. “We have huge growth potential in the U.S.”